FDA's device surveillance process comes under fire in BMJ investigation
This article was originally published in RAJ Devices
The effectiveness of the US Food and Drug Administration's post-approval surveillance of medical devices has been questioned by an investigation published online in the BMJ1. The authors of the article were particularly critical of the agency's Manufacturer and User Facility Device Experience (MAUDE) database, which monitors adverse events linked with approved devices.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.